Tags

Type your tag names separated by a space and hit enter

[Antibacterial treatment of bacteria-abundant leprosy].
Hautarzt. 1983 May; 34(5):203-8.H

Abstract

A historic introduction reviews the start of DDS (diaminodiphenylsulphone) therapy in leprosy, stressing the fact that, far after the start of combined therapy in tuberculosis, leprosy continued to be treated with monotherapy of DDS. Reports about resistance of M. leprae to DDS initiated a review of policy. A complete breakthrough toward combined therapy started after 1962, when Shepard introduced mousefootpad inoculation of M. leprae to be used for therapeutic trials. Full attention is given to Freerksen's trial in Malta where combined treatment with rifampicin, INH, prothionamide, and DDS were given for 2 years only to all patients, while at resurvey after 4 years no relapse was found. The applicability of short-term combined therapy for endemic areas is discussed.

Authors

No affiliation info available

Pub Type(s)

English Abstract
Historical Article
Journal Article

Language

ger

PubMed ID

6345468

Citation

Klokke, A H.. "[Antibacterial Treatment of Bacteria-abundant Leprosy]." Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, vol. 34, no. 5, 1983, pp. 203-8.
Klokke AH. [Antibacterial treatment of bacteria-abundant leprosy]. Hautarzt. 1983;34(5):203-8.
Klokke, A. H. (1983). [Antibacterial treatment of bacteria-abundant leprosy]. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, 34(5), 203-8.
Klokke AH. [Antibacterial Treatment of Bacteria-abundant Leprosy]. Hautarzt. 1983;34(5):203-8. PubMed PMID: 6345468.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Antibacterial treatment of bacteria-abundant leprosy]. A1 - Klokke,A H, PY - 1983/5/1/pubmed PY - 1983/5/1/medline PY - 1983/5/1/entrez SP - 203 EP - 8 JF - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete JO - Hautarzt VL - 34 IS - 5 N2 - A historic introduction reviews the start of DDS (diaminodiphenylsulphone) therapy in leprosy, stressing the fact that, far after the start of combined therapy in tuberculosis, leprosy continued to be treated with monotherapy of DDS. Reports about resistance of M. leprae to DDS initiated a review of policy. A complete breakthrough toward combined therapy started after 1962, when Shepard introduced mousefootpad inoculation of M. leprae to be used for therapeutic trials. Full attention is given to Freerksen's trial in Malta where combined treatment with rifampicin, INH, prothionamide, and DDS were given for 2 years only to all patients, while at resurvey after 4 years no relapse was found. The applicability of short-term combined therapy for endemic areas is discussed. SN - 0017-8470 UR - https://www.unboundmedicine.com/medline/citation/6345468/[Antibacterial_treatment_of_bacteria_abundant_leprosy]_ L2 - https://medlineplus.gov/mycobacterialinfections.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.